Aldeyra Therapeutics Announces $7.79 Million Private

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aldeyra Therapeutics Announces $7.79 Million Private Placement

LEXINGTON, Mass., Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX ) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement to raise approximately $7.79 million in a private placement of common stock and warrants (the Purchase Agreement).  Aldeyra plans to use the proceeds for its upcoming Phase 2 clinical trials in Sjögren-Larsson Syndrome (SLS) and noninfectious anterior uveitis, working capital, and general corporate purposes. The private placement was led by Perceptive Advisors LLC, with participation by Knoll Capital, Sphera Global Healthcare Fund, DAFNA Capital and other accredited investors.

"This financing secures new investment into the company by leading healthcare investors, and it will enable the company to broaden its near-term development plans to include systemic formulations of NS2 and to explore new clinical indications for the molecule, while at the same time strengthen the balance sheet," said Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "As demonstrated with our IND filings in December of 2014 for NS2 in both SLS and noninfectious anterior uveitis, we remain on track with the execution of our business strategy and look forward to collecting further data in support of our lead product candidate."

Pursuant to the terms of the Purchase Agreement, Aldeyra has agreed to sell an aggregate of approximately 1.1 million shares of common stock at a price of $7.00 per share. Investors will also receive warrants to purchase up to approximately 1.1 million shares of common stock at an exercise price of $9.50. The warrants will expire 3 years from the date on which the warrants are issued.  The warrants do not include a net-exercise feature. The warrants may be redeemed by Aldeyra at a price of $0.001 per share upon notice to the holders thereof in the event that the closing bid for Aldeyra's common stock for each of the fifteen consecutive trading days prior to such redemption is at least $20.00 per share and the average trading volume of Aldeyra's common stock during such period is 50,000 shares per day. Following Aldeyra's notification to the warrantholders of its exercise of the redemption right under the warrants, each warrantholder will have the option to exercise their warrants prior to the redemption date rather than having them redeemed.

In addition, Aldeyra is required to file a registration statement for the resale of the shares of common stock issued and issuable pursuant to the warrants. The closing of the offering is subject to the satisfaction of customary closing conditions.

Laidlaw & Company (UK) Ltd. is acting as sole placement agent in connection with this offering.

The securities sold as part of the Purchase Agreement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. Aldeyra has agreed to file a registration statement with the SEC registering the resale of the shares of common stock and the shares underlying the warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to initiate Phase II clinical studies of NS2 in Sjögren-Larsson Syndrome and noninfectious anterior uveitis in early 2015. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding, among other things, the expected closing and closing date of the financing and the use of proceeds of the financing. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; Aldeyra's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov .

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results.  No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 Ext. 205 Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alliance for Women in Media Champions Change in 2026

Updated Category News Views 87

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 141

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 120

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 124

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 61

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 23

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 128

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 199

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Unique Features of Ontomir (OTM) on BitMart

Updated Category News Views 315

Ontomir (OTM) Launches on BitMart Exchange In the world of digital assets, BitMart, a leading global trading platform, has recently showcased its commitment to innovation by announcing the listing of Ontomir (OTM). This launch marks a significant milestone for Ontomir, as the OTM/USDT trading pair becomes available, creating new opportunities for investors. Understanding...

Continue Reading
Vanguard Introduces New Actively Managed Bond ETF for Investors

Updated Category News Views 199

Vanguard Unveils a New Actively Managed Bond ETF Today, Vanguard has proudly introduced the Vanguard Multi-Sector Income Bond ETF (VGMS), a new offering in the realm of actively managed fixed-income exchange-traded funds (ETFs). This innovative product is supervised by the Vanguard Fixed Income Group, known for its extensive expertise in the field. A Commitment to...

Continue Reading
U.S. Markets Experience Mixed Trading Amid Oil Inventory Declines

Updated Category News Views 95

Mixed Performance of U.S. Stocks U.S. stocks displayed a mixed performance during the mid-week trading session, with the S&P 500 edging slightly lower. The markets reacted to various financial reports and inventory levels that influenced trader sentiments. Index Updates The Dow Jones recorded a modest increase, up by 0.08% to 42,267.94. In contrast, the NASDAQ saw a...

Continue Reading
Alignment Healthcare's Strategic Presentation Insights

Updated Category News Views 162

Alignment Healthcare's Upcoming Presentation Alignment Healthcare, Inc. (NASDAQ: ALHC) is making waves in the healthcare sector as it gears up for an important presentation at a renowned healthcare conference. This significant event will take place in January, showcasing the company's commitment to transforming senior care. The Conference Details On January 15, 2025, at...

Continue Reading
Unveiling Talen Energy's Options Trading Trends and Insights

Updated Category News Views 185

Insights into Talen Energy's Recent Options Activity Whales, those significant players in the financial markets, have recently shown a strong bullish interest in Talen Energy. This interest is reflected in a notable increase in options trading activity regarding Talen Energy (NASDAQ: TLN). Understanding the Trading Trends for TLN Within the recent options trading history...

Continue Reading